Laura Shannon and colleagues examine the pathogenesis of pulmonary fibrosis and link the evolving mechanistic insights to current and emerging therapeutic strategies in this review.
Read now in BMJ Medicine: https://bit.ly/3REaoRH
Current treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the disease. These treatments are widely used globally. Emerging agents, such as nerandomilast, showed positive r...
